Fig. 2
Confirmation of 6-OHDA-induced Parkinson’s disease model and AAV8-GFAP-mCherry, AAV8-hM4D(Gi)-mCherry, and AAV8-hM3D(Gq)-mCherry expression in astrocytes. (A) The experimental schedule of 6-OHDA and adeno-associated virus (AAV) injections, cylinder tests, abnormal involuntary movement (AIM) tests, drug administration, and immunohistochemistry (IHC). (B) The percentage of right forelimb use out of the total number of touches made with both paws on the cylinder in the three groups. **p < 0.01 vsersu indicated group (Student’s t-test). (C) The immunostaining images showed TH-positive cells in the substantia nigra of the AAV8-GFAP-mCherry, AAV8-hM4D(Gi)-mCherry, and AAV8-hM3D(Gq)-mCherry groups. Scale bar = 1 mm. (D) Percentage loss of TH-positive cells in the 6-OHDA-lesioned side compared with those in the intact SNc side. One-way analysis of variance [ANOVA] followed by Tukey’s multiple comparisons test. (E) A representative image showing the mCherry expression area in the dorsal striatum (DS) of group AAV8-GFAP-hM4D(Gi)mCherry. Scale bar = 1 mm. CC, corpus callosum; CX, cortex. (F) GFAP-immunostaining, AAV8-mediated mCherry expression, and their co-localization in the dorsal striatum of the mice. Scale bar = 200 μm. (G) NeuN-immunostaining, AAV8-mediated mCherry expression, and their co-localization in the dorsal striatum of the mice. Scale bar = 200 μm. AAV8-GFAP-mCherry, n = 12; AAV8-hM4D(Gi)-mCherry, n = 11; AAV8-hM3D(Gq)-mCherry, n = 10. Data are presented as mean ± SD.
